DK2208784T3 - Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof - Google Patents
Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistofInfo
- Publication number
- DK2208784T3 DK2208784T3 DK10003378.6T DK10003378T DK2208784T3 DK 2208784 T3 DK2208784 T3 DK 2208784T3 DK 10003378 T DK10003378 T DK 10003378T DK 2208784 T3 DK2208784 T3 DK 2208784T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibody
- glypican
- cell proliferation
- proliferation inhibitors
- containing anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001189443 | 2001-06-22 | ||
| EP07002896A EP1780273B1 (en) | 2001-06-22 | 2002-06-21 | Cell proliferation inhibitors containing anti-glypican 3 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2208784T3 true DK2208784T3 (da) | 2013-03-18 |
Family
ID=19028362
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10003378.6T DK2208784T3 (da) | 2001-06-22 | 2002-06-21 | Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof |
| DK02741243T DK1411118T3 (da) | 2001-06-22 | 2002-06-21 | Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02741243T DK1411118T3 (da) | 2001-06-22 | 2002-06-21 | Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20040236080A1 (enExample) |
| EP (3) | EP1780273B1 (enExample) |
| JP (7) | JP4281869B2 (enExample) |
| KR (3) | KR100953520B1 (enExample) |
| CN (2) | CN101240022B (enExample) |
| AT (2) | ATE407204T1 (enExample) |
| AU (2) | AU2002315857B2 (enExample) |
| CA (1) | CA2451493C (enExample) |
| CY (1) | CY1113854T1 (enExample) |
| DE (2) | DE60228721D1 (enExample) |
| DK (2) | DK2208784T3 (enExample) |
| ES (3) | ES2312586T3 (enExample) |
| PT (2) | PT2208784E (enExample) |
| WO (1) | WO2003000883A1 (enExample) |
Families Citing this family (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| PT2208784E (pt) * | 2001-06-22 | 2013-04-03 | Chugai Pharmaceutical Co Ltd | Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3 |
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体 |
| NZ536521A (en) | 2002-05-23 | 2006-04-28 | Sunnybrook And Womenaes Colleg | Diagnosis of hepatocellular carcinoma |
| JPWO2005023301A1 (ja) * | 2003-09-04 | 2006-11-02 | 中外製薬株式会社 | 胆管癌治療剤および検出薬 |
| EP2216046B1 (en) * | 2004-07-09 | 2014-03-12 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| US7871613B2 (en) * | 2004-08-24 | 2011-01-18 | Chugai Seiyaku Kabushiki Kaisha | Adjuvant therapy with the use of anti-glypican 3 antibody |
| RU2451030C2 (ru) * | 2004-10-26 | 2012-05-20 | Чугаи Сейяку Кабусики Кайся | Анти-глипикан 3-антитело, имеющее модифицированную сахарную цепь |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| EP1901573A1 (en) | 2005-08-03 | 2008-03-19 | Matsushita Electric Industrial Co., Ltd. | Base station apparatus, communication terminal apparatus, and multicarrier communication method |
| US20070087005A1 (en) * | 2005-10-14 | 2007-04-19 | Lazar Gregory A | Anti-glypican-3 antibody |
| US7723043B2 (en) | 2006-01-04 | 2010-05-25 | Picobella, Lp | Methods for screening for prostate cancer |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| CN105177091A (zh) * | 2006-03-31 | 2015-12-23 | 中外制药株式会社 | 用于纯化双特异性抗体的抗体修饰方法 |
| CN101815726B (zh) | 2007-07-17 | 2013-04-03 | 米德列斯公司 | 针对磷脂酰肌醇蛋白聚糖-3的单克隆抗体 |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102339457B1 (ko) | 2007-09-26 | 2021-12-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| AR066172A1 (es) | 2007-09-28 | 2009-07-29 | Chugai Pharmaceutical Co Ltd | Metodo para la preparacion de un anticuerpo antiglipicano 3 con modulada cinetica plasmatica mediante variacion de la semivida plasmatica. |
| CA2708532C (en) * | 2007-12-05 | 2018-06-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-il31ra antibody and use thereof |
| CL2009000647A1 (es) * | 2008-04-04 | 2010-06-04 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto. |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| WO2010107109A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| US10150808B2 (en) | 2009-09-24 | 2018-12-11 | Chugai Seiyaku Kabushiki Kaisha | Modified antibody constant regions |
| EP2543730B1 (en) | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| RU2620071C2 (ru) | 2010-11-17 | 2017-05-22 | Чугаи Сеияку Кабушики Каиша | Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii |
| TWI807362B (zh) | 2010-11-30 | 2023-07-01 | 日商中外製藥股份有限公司 | 細胞傷害誘導治療劑 |
| BR112013013354A2 (pt) | 2010-11-30 | 2020-10-06 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente |
| US20120190049A1 (en) * | 2010-12-10 | 2012-07-26 | University Of Washington Through Its Center For Commercialization | Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles |
| EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
| AU2012233313C1 (en) | 2011-03-30 | 2017-08-03 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
| TWI681970B (zh) | 2011-09-30 | 2020-01-11 | 日商中外製藥股份有限公司 | 包含依離子濃度之條件對抗原之結合活性會改變之抗原結合分域、及於pH中性之條件下對FcRn有結合活性之FcRn結合分域、且誘導對標的抗原的免疫反應之抗原結合分子 |
| JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| KR20200096692A (ko) | 2011-09-30 | 2020-08-12 | 추가이 세이야쿠 가부시키가이샤 | 항원의 소실을 촉진시키는 항원 결합 분자 |
| TW201326209A (zh) | 2011-09-30 | 2013-07-01 | Chugai Pharmaceutical Co Ltd | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| JP6271251B2 (ja) | 2011-10-05 | 2018-01-31 | 中外製薬株式会社 | 糖鎖受容体結合ドメインを含む抗原の血漿中からの消失を促進する抗原結合分子 |
| CA2865158C (en) | 2012-02-24 | 2022-11-01 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib |
| KR102677704B1 (ko) | 2012-05-30 | 2024-06-21 | 추가이 세이야쿠 가부시키가이샤 | 표적 조직 특이적 항원 결합 분자 |
| US9409994B2 (en) | 2012-06-01 | 2016-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| EP4119947A1 (en) | 2012-12-21 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy |
| TWI693073B (zh) | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑 |
| CN105764922B (zh) | 2013-09-27 | 2020-07-17 | 中外制药株式会社 | 多肽异源多聚体的制备方法 |
| KR102454360B1 (ko) | 2013-12-04 | 2022-10-12 | 추가이 세이야쿠 가부시키가이샤 | 화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리 |
| US11760807B2 (en) | 2014-05-08 | 2023-09-19 | Chugai Seiyaku Kabushiki Kaisha | GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapy |
| US9926377B2 (en) * | 2014-05-22 | 2018-03-27 | Genentech, Inc. | Anti-GPC3 antibodies and immunoconjugates |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| CN104829704B (zh) * | 2014-12-15 | 2016-08-17 | 河北省科学院生物研究所 | 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株 |
| MY181199A (en) | 2014-12-19 | 2020-12-21 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| TWI617580B (zh) | 2014-12-19 | 2018-03-11 | 中外製藥股份有限公司 | 抗ｃ５抗體及使用方法 |
| KR102435383B1 (ko) * | 2015-01-16 | 2022-08-24 | 미노믹 인터내셔널 리미티드 | 글리피칸 에피토프 및 이의 용도 |
| CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il‑8‑结合抗体，及其应用 |
| RU2730590C2 (ru) | 2015-02-27 | 2020-08-24 | Чугаи Сейяку Кабусики Кайся | Композиция для лечения заболеваний, связанных с ил-6 |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| EP3318879B1 (en) | 2015-07-01 | 2020-10-21 | Chugai Seiyaku Kabushiki Kaisha | Gpc3-targeting therapeutic agent which is administered to patient for whom the gpc3-targeting therapeutic agent is effective |
| CN106397593B (zh) * | 2015-08-03 | 2019-09-10 | 科济生物医药（上海）有限公司 | 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用 |
| KR101796688B1 (ko) | 2015-10-29 | 2017-12-01 | 재단법인 목암생명과학연구소 | 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물 |
| SI3373968T1 (sl) | 2015-11-09 | 2024-10-30 | The Children's Hospital Of Philadelphia | Glipikan 2 kot marker raka in terapevtska tarča |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CA3004288C (en) | 2015-12-28 | 2025-05-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION |
| BR112018068363A2 (pt) | 2016-03-14 | 2019-01-15 | Chugai Seiyaku Kabushiki Kaisha | fármaco terapêutico indutor de dano celular para uso em terapia de câncer |
| WO2017159699A1 (en) * | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
| TWI820000B (zh) | 2016-04-28 | 2023-11-01 | 日商中外製藥股份有限公司 | 含抗體製劑 |
| JP6527643B2 (ja) | 2016-08-05 | 2019-06-05 | 中外製薬株式会社 | Ｉｌ−８関連疾患の治療用又は予防用組成物 |
| JP7125347B2 (ja) | 2016-08-22 | 2022-08-24 | 中外製薬株式会社 | ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物 |
| KR102533814B1 (ko) | 2016-11-28 | 2023-05-19 | 추가이 세이야쿠 가부시키가이샤 | 리간드 결합 활성을 조정 가능한 리간드 결합 분자 |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| WO2019059411A1 (en) | 2017-09-20 | 2019-03-28 | Chugai Seiyaku Kabushiki Kaisha | DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT |
| AR113816A1 (es) | 2017-11-01 | 2020-06-17 | Chugai Pharmaceutical Co Ltd | Variantes e isoformas de anticuerpos con actividad biológica reducida |
| TWI818934B (zh) | 2017-11-28 | 2023-10-21 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| AR114112A1 (es) | 2018-02-15 | 2020-07-22 | Seattle Genetics Inc | Anticuerpos de glipicano 3 y conjugados de los mismos |
| US20210253672A1 (en) | 2018-05-30 | 2021-08-19 | Chugai Seiyaku Kabushiki Kaisha | Ligand-binding molecule containing single domain antibody |
| TWI809130B (zh) | 2018-06-22 | 2023-07-21 | 美商凱特製藥公司 | 嵌合跨膜蛋白及其用途 |
| AU2019354395A1 (en) | 2018-10-01 | 2021-05-06 | Adicet Therapeutics, Inc. | Compositions and methods regarding engineered and non-engineered γδ -T cells for treatment of solid tumors |
| PE20211279A1 (es) | 2018-10-23 | 2021-07-19 | Dragonfly Therapeutics Inc | Proteinas heterodimericas fusionadas con fc |
| US20220153875A1 (en) | 2019-03-19 | 2022-05-19 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain |
| WO2020246567A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | プロテアーゼ基質、及びプロテアーゼ切断配列を含むポリペプチド |
| CN113905757A (zh) | 2019-06-05 | 2022-01-07 | 中外制药株式会社 | 抗体切割位点结合分子 |
| JP2022536975A (ja) | 2019-06-21 | 2022-08-22 | カイト ファーマ インコーポレイテッド | ＴＧＦ－β受容体及び使用方法 |
| MX2022013112A (es) | 2020-04-22 | 2023-01-16 | Dragonfly Therapeutics Inc | Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc. |
| CN116194124A (zh) | 2020-07-31 | 2023-05-30 | 中外制药株式会社 | 包含表达嵌合受体的细胞的药物组合物 |
| CN118488970A (zh) * | 2021-10-15 | 2024-08-13 | 乐普创一生物科技（上海）有限公司 | 抗磷脂酰肌醇蛋白聚糖3抗体 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04228089A (ja) | 1990-05-15 | 1992-08-18 | Kanegafuchi Chem Ind Co Ltd | 高カルシウム血症治療・予防剤 |
| WO1995014041A1 (en) * | 1993-11-19 | 1995-05-26 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human medulloblastomatous cell |
| EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
| UA76934C2 (en) * | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
| JP3587664B2 (ja) | 1996-10-04 | 2004-11-10 | 中外製薬株式会社 | 再構成ヒト抗ｈｍ１．２４抗体 |
| JP4228089B2 (ja) | 1997-03-11 | 2009-02-25 | 株式会社ニコン | 過電流検知機構およびそれを用いた電子閃光装置 |
| US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
| CN1277632A (zh) * | 1997-10-03 | 2000-12-20 | 中外制药株式会社 | 天然人源化抗体 |
| JP3445153B2 (ja) | 1998-06-04 | 2003-09-08 | 富士通株式会社 | 電話番号一時的使用装置及び方法 |
| TWI290832B (en) | 1999-08-23 | 2007-12-11 | Chugai Pharmaceutical Co Ltd | Expression enhancer for HM1.24 antigen |
| PT2208784E (pt) * | 2001-06-22 | 2013-04-03 | Chugai Pharmaceutical Co Ltd | Inibidores da proliferação celular contendo um anticorpo anti-glipicano 3 |
-
2002
- 2002-06-21 PT PT100033786T patent/PT2208784E/pt unknown
- 2002-06-21 AU AU2002315857A patent/AU2002315857B2/en not_active Expired
- 2002-06-21 KR KR1020097019979A patent/KR100953520B1/ko not_active Expired - Lifetime
- 2002-06-21 KR KR1020037016776A patent/KR100877176B1/ko not_active Expired - Lifetime
- 2002-06-21 KR KR1020087019090A patent/KR20080077295A/ko not_active Ceased
- 2002-06-21 CN CN2007100960379A patent/CN101240022B/zh not_active Expired - Lifetime
- 2002-06-21 DK DK10003378.6T patent/DK2208784T3/da active
- 2002-06-21 CN CNB028125703A patent/CN1314803C/zh not_active Expired - Lifetime
- 2002-06-21 PT PT02741243T patent/PT1411118E/pt unknown
- 2002-06-21 EP EP07002896A patent/EP1780273B1/en not_active Expired - Lifetime
- 2002-06-21 ES ES02741243T patent/ES2312586T3/es not_active Expired - Lifetime
- 2002-06-21 WO PCT/JP2002/006237 patent/WO2003000883A1/ja not_active Ceased
- 2002-06-21 CA CA2451493A patent/CA2451493C/en not_active Expired - Lifetime
- 2002-06-21 AT AT02741243T patent/ATE407204T1/de active
- 2002-06-21 ES ES07002896T patent/ES2353335T3/es not_active Expired - Lifetime
- 2002-06-21 DK DK02741243T patent/DK1411118T3/da active
- 2002-06-21 EP EP10003378A patent/EP2208784B1/en not_active Expired - Lifetime
- 2002-06-21 AT AT07002896T patent/ATE483801T1/de not_active IP Right Cessation
- 2002-06-21 JP JP2003507268A patent/JP4281869B2/ja not_active Expired - Lifetime
- 2002-06-21 US US10/481,524 patent/US20040236080A1/en not_active Abandoned
- 2002-06-21 EP EP02741243A patent/EP1411118B1/en not_active Expired - Lifetime
- 2002-06-21 DE DE60228721T patent/DE60228721D1/de not_active Expired - Lifetime
- 2002-06-21 DE DE60237929T patent/DE60237929D1/de not_active Expired - Lifetime
- 2002-06-21 ES ES10003378T patent/ES2399028T3/es not_active Expired - Lifetime
-
2005
- 2005-04-28 JP JP2005133154A patent/JP2005225892A/ja not_active Withdrawn
-
2006
- 2006-11-06 JP JP2006300276A patent/JP2007051159A/ja not_active Withdrawn
-
2007
- 2007-02-05 US US11/702,780 patent/US7744880B2/en not_active Expired - Lifetime
- 2007-03-22 AU AU2007201255A patent/AU2007201255B2/en not_active Expired
- 2007-06-25 JP JP2007165739A patent/JP2007238632A/ja active Pending
-
2008
- 2008-02-08 JP JP2008028527A patent/JP2008120828A/ja active Pending
- 2008-09-05 JP JP2008228128A patent/JP4347402B2/ja not_active Expired - Lifetime
-
2009
- 2009-04-24 JP JP2009105835A patent/JP5596935B2/ja not_active Expired - Lifetime
-
2010
- 2010-04-26 US US12/799,491 patent/US8263077B2/en not_active Expired - Fee Related
-
2013
- 2013-03-29 CY CY20131100264T patent/CY1113854T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2208784T3 (da) | Celleproliferationsinhibitorer indeholdende anti-glypican-3-antistof | |
| BRPI0317696B8 (pt) | composição para branqueamento | |
| ATE363280T1 (de) | Verwendung von pioglitazone zur verbesserung der ketose und der azidose | |
| GB0209891D0 (en) | Novel compounds | |
| CY1106766T1 (el) | Παραγωγα πυριδινης ως αναστολεις raf κινασης | |
| SE0102327D0 (sv) | A novel engineered superantigen for human therapy | |
| TR200002480T2 (tr) | İzaşemi tedavisi için guanidin türevleri | |
| BRPI0410467A (pt) | composições e métodos para tratamento de sìndrome respiratória aguda severa (sars) | |
| TR200200883T2 (tr) | 2-ikameli 1,1-bifenil-2-karbonamidler, imalat yöntemleri, ilaç olarak kullanılmaları | |
| IL156774A0 (en) | Inhibitors of cruzipain and other cysteine proteases | |
| BR0014758A (pt) | Sistemas e métodos para expressão de proteìna com alto rendimento | |
| ATE404602T1 (de) | Wässrige polyurethanzubereitungen | |
| DE50009838D1 (de) | Humanes antibiotisches protein | |
| DE69931784D1 (de) | Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung | |
| DK1368022T3 (da) | Anvendelse af en flaske indeholdende en oxaliplatinoplösning | |
| IT1317049B1 (it) | Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv. | |
| DK1244643T3 (da) | Tryptaseinhibitorer | |
| ATE392644T1 (de) | Alpha-(1' -hydroxyalkyl)acrylate enthaltende beschichtungsmassen | |
| DK1244614T3 (da) | Tryptase-inhibitorer | |
| DE502004012439D1 (de) | Medikament und verwendung zur tumortherapie | |
| DK1438411T3 (da) | Anvendelse af aminogylcosid-resistensgen | |
| DK0733370T3 (da) | Anvendelse af en genpromotorsekvens til behandling af rheumatiske sygdomme | |
| PT1380208E (pt) | Agente desinfectante com actividade antiparasitica | |
| ATE382363T1 (de) | Pharmazeutische zusammensetzung enthaltend bulbophyllum | |
| TW200505413A (en) | Intermediates useful in the synthesis of hiv-protease inhibitors and methods for preparing the same |